<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02758431</url>
  </required_header>
  <id_info>
    <org_study_id>15-1162</org_study_id>
    <secondary_id>UL1TR001082</secondary_id>
    <nct_id>NCT02758431</nct_id>
  </id_info>
  <brief_title>Cardiovascular Outcomes of Low Testosterone</brief_title>
  <acronym>CardioVOLT</acronym>
  <official_title>Cardiovascular Consequences of Hypogonadism in Men</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Colorado, Denver</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Colorado, Denver</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study plans to learn more about heart and vascular aging in men. In some men as they get&#xD;
      older, testosterone levels fall below the normal range for young men. Also, as men get older&#xD;
      cardiovascular health worsens. This can lead to high blood pressure and heart disease. In&#xD;
      this study we want to find out what causes cardiovascular health to worsen in older men. Also&#xD;
      we want to find out what happens when testosterone levels are lowered for a short time.&#xD;
      Specifically, we want to see if the reduction in cardiovascular health in older men with low&#xD;
      testosterone levels is because of damage to mitochondria. Mitochondria are the main power&#xD;
      supply of the cells in our body. The results from this study will help to understand why&#xD;
      cardiovascular health declines in older men with low testosterone levels compared to younger&#xD;
      men and older men who have higher testosterone levels. Knowing this information will help to&#xD;
      develop therapies to prevent heart disease in men.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Cardiovascular (CV) aging, featuring large artery stiffening, endothelial dysfunction, and&#xD;
      impaired left ventricular (LV) diastolic function, is a major risk factor for the development&#xD;
      of cardiovascular diseases (CVD). Male aging is associated with a gradual and variable&#xD;
      decline in serum testosterone (T) and low T is associated with accelerated CV aging. The&#xD;
      purpose of this research is to determine the key functional mechanisms underlying accelerated&#xD;
      CV aging in older men with low T. The overall hypothesis is that mitochondrial dysfunction&#xD;
      and oxidative stress are mechanisms underlying the apparent accelerated CV aging in older men&#xD;
      with low T. To test this hypothesis Aim 1 will use cross-sectional comparisons of young and&#xD;
      older men with normal T (≥400 ng/dl), and older men with chronically low T (&lt;300 ng/dl). To&#xD;
      better isolate the effects of low T from factors that change with aging and chronic low T,&#xD;
      Aim 2 will expand on the cross-sectional comparisons by assessing measures of CV function,&#xD;
      oxidative stress burden and mitochondrial function in older men with normal T before and&#xD;
      after randomization to short-term (28 d) gonadal suppression (gonadotropin releasing hormone&#xD;
      antagonist, GnRHant) + placebo (PL), GnRHant+T alone, or GnRHant+T+aromatase inhibitor (AI).&#xD;
      AI will control for the effects of aromatization of T to estradiol (E2), and thereby isolate&#xD;
      T effects while suppressing E2, a potent modulator of CV function. The results from this&#xD;
      research should provide new mechanistic insight into the processes that mediate the&#xD;
      impairment in CV function at the cellular and systemic level in older men with low T. These&#xD;
      studies will lead to a better understanding of the independent role of T in age-related&#xD;
      changes in CV function and the mechanisms of action, which will help guide future&#xD;
      sex-specific therapies for the prevention of CVD.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>February 2016</start_date>
  <completion_date type="Anticipated">November 2022</completion_date>
  <primary_completion_date type="Anticipated">September 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Endothelial function</measure>
    <time_frame>Change from baseline at 28 days</time_frame>
    <description>Brachial artery flow-mediated dilation, and EndoPAT™</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Carotid artery compliance</measure>
    <time_frame>Change from baseline at 28 days</time_frame>
    <description>Carotid artery compliance and beta stiffness index</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Arterial stiffness</measure>
    <time_frame>Change from baseline at 28 days</time_frame>
    <description>Pulse-wave velocity</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Left ventricular diastolic function</measure>
    <time_frame>Change from baseline at 28 days</time_frame>
    <description>Measured via Cardiac Echo</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>NADPH oxidase</measure>
    <time_frame>Change from baseline at 28 days</time_frame>
    <description>Oxidative stress marker measured in endothelial cells</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Nitrotyrosine</measure>
    <time_frame>Change from baseline at 28 days</time_frame>
    <description>Measured in endothelial cells</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MnSOD</measure>
    <time_frame>Change from baseline at 28 days</time_frame>
    <description>Mitochondrial superoxide dismutase measured in endothelial cells</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>eNOS</measure>
    <time_frame>Change from baseline at 28 days</time_frame>
    <description>Endothelial nitric oxide synthase (eNOS) measured in endothelial cell</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>COX IV</measure>
    <time_frame>Change from baseline at 28 days</time_frame>
    <description>Marker of mitochondrial function measured in PBMCs</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mitochondrial RCR</measure>
    <time_frame>Change from baseline at 28 days</time_frame>
    <description>Mitochondrial respiration measured via Oroboros O2K</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Supine blood pressure</measure>
    <time_frame>Change from baseline at 28 days</time_frame>
    <description>On the cardiovascular testing days, supine blood pressure will be measured in triplicate.</description>
  </other_outcome>
  <other_outcome>
    <measure>Body Composition</measure>
    <time_frame>Baseline</time_frame>
    <description>Whole body and regional body composition will be determined using dual energy x-ray absorptiometry for subject characteristics and for the determination of fat-free mass for the AA dose preparation.</description>
  </other_outcome>
  <other_outcome>
    <measure>Plasma Lipid Concentrations</measure>
    <time_frame>Baseline</time_frame>
    <description>Plasma lipid concentrations, including total-cholesterol (C) and triglycerides (TG) will be determined at baseline. The rationale for making these measurements is for screening criteria, subject characteristics, and because they may correlate with CV function.</description>
  </other_outcome>
  <other_outcome>
    <measure>Glucose Concentrations</measure>
    <time_frame>Change from baseline at 28 days</time_frame>
    <description>Fasted glucose concentrations will be measured at screening and at each vascular test.</description>
  </other_outcome>
  <other_outcome>
    <measure>Sex Hormones</measure>
    <time_frame>Change from baseline at 28 days</time_frame>
    <description>Serum concentrations of total testosterone (T), estradiol, albumin, sex hormone binding globulin (SHBG), luteinizing hormone and follicle stimulating hormone will be measured to document changes in hormone concentrations and free T will be calculated using the known affinity constants of T for SHBG and for albumin. Additional measures of T will be measured after 60 days if testosterone has not returned to baseline. The 60 day plus measures are for safety.</description>
  </other_outcome>
  <other_outcome>
    <measure>Endothelin-1 (ET-1)</measure>
    <time_frame>Change from baseline at 28 days</time_frame>
    <description>Plasma ET-1 will be measured because it is a potent vasoconstrictor and has complex interactions with NO. Specifically, ET-1 synthesis is under tonic inhibition by NO.</description>
  </other_outcome>
  <other_outcome>
    <measure>Physical Activity Levels</measure>
    <time_frame>Change from baseline at 28 days</time_frame>
    <description>To document the habitual physical activity status at baseline and the last week of respective interventions, daily energy expenditure will be estimated using ActivPal monitors.</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">379</enrollment>
  <condition>Hypogonadism</condition>
  <arm_group>
    <arm_group_label>Group 1: Acyline plus placebo (No Testosterone Add-Back)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Acyline plus placebo gel and placebo tablet.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2: Acyline plusTestosterone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Acyline plus transdermal testosterone gel plus placebo tablet.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3: Acyline plus Testosterone plus Arimidex)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Acyline plus transdermal testosterone gel plus Aromatase inhibitor (Arimidex) oral.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Acyline</intervention_name>
    <description>Acyline 300ug/kg injection will be administered on Day 0 and on day 14</description>
    <arm_group_label>Group 1: Acyline plus placebo (No Testosterone Add-Back)</arm_group_label>
    <arm_group_label>Group 2: Acyline plusTestosterone</arm_group_label>
    <arm_group_label>Group 3: Acyline plus Testosterone plus Arimidex)</arm_group_label>
    <other_name>Gonadotropin releasing hormone antagonist</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Gel</intervention_name>
    <description>Placebo gel packet applied daily for 28 days.</description>
    <arm_group_label>Group 1: Acyline plus placebo (No Testosterone Add-Back)</arm_group_label>
    <other_name>Placebo</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Tablet</intervention_name>
    <description>Placebo oral tablet taken daily for 28 days.</description>
    <arm_group_label>Group 1: Acyline plus placebo (No Testosterone Add-Back)</arm_group_label>
    <arm_group_label>Group 2: Acyline plusTestosterone</arm_group_label>
    <other_name>Placebo</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Testosterone Gel</intervention_name>
    <description>Testosterone Gel applied daily for 28 days</description>
    <arm_group_label>Group 2: Acyline plusTestosterone</arm_group_label>
    <arm_group_label>Group 3: Acyline plus Testosterone plus Arimidex)</arm_group_label>
    <other_name>Transdermal Testosterone Gel</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Arimidex</intervention_name>
    <description>Arimidex Oral Tablet 1mg taken orally daily for 28 days</description>
    <arm_group_label>Group 3: Acyline plus Testosterone plus Arimidex)</arm_group_label>
    <other_name>Aromatase inhibitor</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Men aged 18-40 years and 50-75 years&#xD;
&#xD;
          2. Chronically low testosterone group will have testosterone concentrations &lt;300 ng/dl,&#xD;
             and young and older normal testosterone groups will have testosterone levels 400-1000&#xD;
             ng/dl&#xD;
&#xD;
          3. No use of sex hormones for at least 1 year&#xD;
&#xD;
          4. Body mass index &lt;40 kg/m2&#xD;
&#xD;
          5. Nonsmokers&#xD;
&#xD;
          6. Resting blood pressure &lt;160/90 mmHg&#xD;
&#xD;
          7. Fasting plasma glucose &lt;126 mg/dL&#xD;
&#xD;
          8. Healthy, as determined by medical history, physical examination, standard blood&#xD;
             chemistries (chemistry panel, complete blood clot and circulating thyroid levels) and&#xD;
             a graded exercise stress test with monitoring of blood pressure and electrocardiogram&#xD;
             (ECG)&#xD;
&#xD;
          9. Sedentary or recreationally active (&lt; 3 days/wk of vigorous aerobic exercise)&#xD;
&#xD;
         10. No use of medications that might influence cardiovascular function including&#xD;
             anti-hypertensive, lipid lowering medications, and corticosteroids&#xD;
&#xD;
         11. No use of vitamin supplements or anti-inflammatory medications, or willing to stop 1&#xD;
             month prior and throughout the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Contraindications to:&#xD;
&#xD;
               1. Gonadotropin releasing hormone (GnRH) antagonist&#xD;
&#xD;
               2. Testosterone gel and aromatase inhibitor including hypersensitivity to Acyline,&#xD;
                  Androgel®, Arimidex®&#xD;
&#xD;
               3. Extrinsic peptide hormones, mannitol, GnRH or any other GnRH analogs&#xD;
&#xD;
          2. History of or active prostate or breast cancer or other sex hormone-dependent&#xD;
             neoplasms&#xD;
&#xD;
          3. Pre-existing or active cardiac, renal or hepatic disease&#xD;
&#xD;
          4. History of stomach ulcer or bleeding&#xD;
&#xD;
          5. History of epilepsy or other seizure disorder&#xD;
&#xD;
          6. Diabetes&#xD;
&#xD;
          7. Active infection&#xD;
&#xD;
          8. Disease that affects the nervous system&#xD;
&#xD;
          9. Abnormal resting ECG&#xD;
&#xD;
        Additionally, men participating in the gonadal suppression intervention study will do so&#xD;
        with the understanding that they will be randomly assigned to study groups that involve&#xD;
        either GnRH antagonist plus testosterone gel plus placebo tablet (33% chance), GnRH&#xD;
        antagonist plus testosterone gel plus aromatase inhibitor tablet (33% chance) or GnRH&#xD;
        antagonist plus placebo gel plus placebo tablet (33% chance).&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kerrie Moreau, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Colorado, Denver</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kerrie Moreau, PhD</last_name>
    <phone>303-724-1914</phone>
    <email>kerrie.moreau@ucdenver.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Colorado CCTSI CTRC</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kerrie Moreau, PhD</last_name>
      <phone>303-724-1914</phone>
      <email>kerrie.moreau@ucdenver.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>April 20, 2016</study_first_submitted>
  <study_first_submitted_qc>April 29, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 2, 2016</study_first_posted>
  <last_update_submitted>October 25, 2021</last_update_submitted>
  <last_update_submitted_qc>October 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>testosterone</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypogonadism</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methyltestosterone</mesh_term>
    <mesh_term>Anastrozole</mesh_term>
    <mesh_term>Testosterone</mesh_term>
    <mesh_term>Testosterone undecanoate</mesh_term>
    <mesh_term>Testosterone enanthate</mesh_term>
    <mesh_term>Testosterone 17 beta-cypionate</mesh_term>
    <mesh_term>Aromatase Inhibitors</mesh_term>
    <mesh_term>Acyline</mesh_term>
    <mesh_term>Hormone Antagonists</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

